ライフサイエンスコーパス: chromogranin

1 he fragment reversed the enhancing effect of chromogranin.

2 o-aggregation of other proteins, such as the chromogranins.

3 in, performance status, tumor burden, plasma chromogranin A (>/=600 mug/L), neuron-specific enolase (

4 PA PET/CT results had higher values of serum chromogranin A (100% vs. 20%, P = 0.0003), serotonin, or

5 strin (1031 pg/ml; reference value <108) and chromogranin A (337 U/L; reference value <36).

6 ol as a well-known marker of stress loading, chromogranin A (CgA) and alpha-amylase (AA) are supposed

7 Results showed that proteolytic fragments of chromogranin A (CgA) and chromogranin B (CgB) represent

8 secretory vesicles of neuroendocrine cells, chromogranin A (CGA) and chromogranin B (CGB), have been

9 LDCV formation involves the granin proteins chromogranin A (CgA) and chromogranin B (CgB); CgA- and

10 nocarcinomas correlates with serum levels of chromogranin A (CgA) and drives treatment resistance.

11 Chromogranin A (CgA) and neuron-specific enolase (NSE) w

12 Immunohistochemical (IHC) measurement of chromogranin A (CgA) discriminates gastrointestinal (GI)

13 Previously, chromogranin A (CgA) has been shown to play a key role i

14 afficking of the regulated secretory protein chromogranin A (CgA) in PC12 cells.

15 Chromogranin A (CgA) is the major soluble protein in the

16 Chromogranin A (CgA) levels have previously been found t

17 Chromogranin A (CgA) may be critical for secretory granu

18 n active 21-residue peptide derived from the chromogranin A (CgA) precursor, and catestatin is secret

19 In neuroendocrine tumors (NETs), Chromogranin A (CgA) was considered acceptable as a biom

20 iated with increased cleavage of full-length chromogranin A (CgA), a circulating vasoregulatory neuro

21 ing and organ colonization were inhibited by chromogranin A (CgA), a protein present in variable amou

22 ctors to 125 species and observed that fecal chromogranin A (CgA), a protein secreted by enteroendocr

23 found that physiologic levels of circulating chromogranin A (CgA), a protein secreted by the neuroend

24 stores in which the Ca(2+) storage protein, chromogranin A (CGA), couples with InsP(3)-gated Ca(2+)

25 gnosis is established by elevation of plasma chromogranin A (CgA), serotonin, or urinary 5-hydroxyind

26 r Musashi-1 (Msi-1), neurogenin 3 (NEUROG3), chromogranin A (CgA), serotonin, peptide YY (PYY), oxynt

27 Chromogranin A (CgA), the major soluble protein in catec

28 Chromogranin A (CgA), which binds catecholamines for sto

29 e neuroendocrine (NE) markers calcitonin and chromogranin A (CgA).

30 cription of the major vesicular core protein chromogranin A (CgA).

31 secretion in endocrine cells is dependent on chromogranin A (CGA).

32 age product of the neuroendocrine prohormone chromogranin A (CgA).

33 n, increased tumor grade, and elevated serum chromogranin A (CgA).

34 cells, we show that SgIII is complexed with Chromogranin A (CgA).

35 the N- and C-terminal regions of circulating chromogranin A (CgA, CHGA), classically an antiangiogeni

36 Chromogranin A (CHGA) and its derived peptides, which ar

37 n C-peptide fragment fused to a peptide from chromogranin A (ChgA) and that endogenous 2.5HIP-reactiv

38 es, we have identified the peptide WE14 from chromogranin A (ChgA) as the antigen for highly diabetog

39 , which is a fusion of insulin C-peptide and chromogranin A (ChgA) fragments, and compared it with th

40 Chromogranin A (ChgA) has been identified as the antigen

41 Recent studies suggest an important role of chromogranin A (CHGA) in the regulated secretory pathway

42 Chromogranin A (ChgA) is an autoantigen for CD4(+) T cel

43 The acidic glycoprotein chromogranin A (CHGA) is co-stored/co-secreted with cate

44 Chromogranin A (CHGA) is coreleased with catecholamines

45 The secretory pro-hormone chromogranin A (CHGA) is densely packed into storage gra

46 The secretory prohormone chromogranin A (CHGA) is overexpressed in essential hype

47 etermine whether the common variation at the chromogranin A (CHGA) locus increases susceptibility to

48 Whether chromogranin A (CHGA) polymorphisms predict end-organ co

49 Chromogranin A (CHGA) regulates catecholamine storage an

50 Chromogranin A (CHGA) regulates the storage and release

51 Chromogranin A (CHGA) triggers catecholamine secretory g

52 mimotope (BDC2.5(mim)) of islet autoantigen chromogranin A (ChgA) with or without calcitriol (1alpha

53 Chromogranin A (CHGA), a protein released from secretory

54 mine release inhibitory peptide derived from chromogranin A (CHGA), and other CHGA- or chromogranin B

55 ied the beta cell secretory granule protein, chromogranin A (ChgA), as a new autoantigen in type 1 di

56 tide derived from the neuroendocrine protein chromogranin A (CHGA), is a functional AMP and is presen

57 Chromogranin A (Chga), which catalyzes formation and car

58 Catestatin (CST), a chromogranin A (CHGA)-derived peptide, is a potent inhib

59 Chromogranin A (CHGA/Chga), a proprotein, widely distrib

60 esicular monoamine transporter (VMAT1,2) and chromogranin A (ChrgA), are also expressed in taste buds

61 Hybrid-insulin C-chromogranin A (InsC-ChgA)-specific CD4(+) T cells skewe

62 ng for mucosal 5-HT synthesis; P < 0.01] and chromogranin A (neuroendocrine secretion; P < 0.01), wit

63 and neuroendocrine markers synaptophysin and chromogranin A (P < 0.0000001).

64 s of the CT pulmonary angiographic findings, chromogranin A and 5-hydroxyindoleacetic acid levels wer

65 Tumor markers (chromogranin A and 5-hydroxyindoleacetic acid) before an

66 levels of oxytocin and peptides derived from chromogranin A and B dramatically decreased in the PC1 K

67 proopiomelanocortin, protachykinins A and B, chromogranin A and B, and secretogranin II.

68 ically abolished regulated secretion of both chromogranin A and beta-endorphin in response to the usu

69 GFI1 colocalizes with chromogranin A and calcitonin-gene-related peptide in em

70 nclude insulin and the two new autoantigens, chromogranin A and islet amyloid polypeptide, all protei

71 Thus, chromogranin A and its catestatin fragment may lie at th

72 eals that the interaction between fragmented chromogranin A and neuropilin-1 is required for tumor gr

73 a radioimmunoassays showed elevated gastrin, chromogranin A and normal levels of gastrin-releasing pe

74 Staining is negative for chromogranin A and positive for bombesin, serotonin, neu

75 alize with secretory granule markers such as chromogranin A and Rab27b, whereas Myo5c tubules are lab

76 r panendocrine immunohistochemistry markers (chromogranin A and/or synaptophysin); 35% of NETs demons

77 Chromogranin A appears to be the most useful serum marke

78 In summary, common variants in chromogranin A associate with the risk of hypertensive E

79 efore probed the role of the MAPK pathway in chromogranin A biosynthesis after secretory stimulation

80 We investigated the effects of a novel chromogranin A catecholamine release-inhibitory fragment

81 t, removing the C-terminal 90 amino acids of chromogranin A caused rerouting to the constitutive secr

82 ells revealed reciprocal changes in secreted chromogranin A COOH-terminal fragments (increased approx

83 Point mutations of the chromogranin A CRE suggested that this element was neces

84 Both the MAPK pathway and chromogranin A expression may be activated by cytosolic

85 ues representing subsequent recurrences, the Chromogranin A expression was lost, and the Ki-67 index

86 Serum markers include chromogranin A for neuroendocrine tumors, pepsinogen I f

87 tely 71 and approximately 27 kD NH2-terminal chromogranin A fragments.

88 PACAP activated the endogenous chromogranin A gene by four- to fivefold.

89 IGF-I stimulated chromogranin A gene expression by Northern blot analysis

90 led with assay of histidine decarboxylase or chromogranin A gene expression is useful in the assessme

91 ed whether PACAP regulates expression of the chromogranin A gene in PC12 rat chromaffin cells, so as

92 Chromogranin A immunoblots revealed chromogranin A proce

93 tion was used to analyze the distribution of chromogranin A immunoreactive cells in serial sections o

94 injection, total insulin content and insulin:chromogranin A immunoreactivity were reduced by approxim

95 hemistry demonstrated a relative decrease of chromogranin A in processes (where regulated secretory v

96 retory granules, and stimulated secretion of chromogranin A increased 50%.

97 Specific endopeptidases cleave chromogranin A into biologically active peptide fragment

98 These results demonstrate that chromogranin A is a substrate for the endogenous endopro

99 The catestatin fragment of chromogranin A is an endogenous inhibitor of nicotinic c

100 The catestatin fragment of chromogranin A is an inhibitor of catecholamine release,

101 This region of chromogranin A is extensively processed within chromaffi

102 Chromogranin A is released together with epinephrine and

103 Since chromogranin A is secreted along with catecholamines, we

104 Chromogranin A is the major soluble core component in se

105 Chromogranin A knock-out (Chga-KO) mice display increase

106 Chromogranin A knockout (Chga-KO) mice exhibit enhanced

107 ng a greater than 50% reduction in the nadir chromogranin A level within the 1st year after treatment

108 estimated absorbed BM dose, elevated plasma chromogranin A level, baseline blood counts, and renal f

109 Her 5-hydroxyindoleacetic acid and chromogranin A levels were not elevated.

110 Chromogranin A levels were significantly higher in both

111 rmal, as were 5-hydroxyindoleacetic acid and chromogranin A levels.

112 on of PCl suggests that the action of PC1 on chromogranin A may be specific within the chromogranin/s

113 and calcitonin and suggest that the role of chromogranin A may be to stabilize an otherwise unstable

114 This small domain within chromogranin A may contribute to a novel, autocrine, hom

115 owledge of cleavage sites of catestatin from chromogranin A may provide a useful starting point in an

116 function, e.g., histidine decarboxylase and chromogranin A messenger RNA abundance, in carcinoid tum

117 NH2-terminal fragment as well as the parent chromogranin A molecule accumulated, while an approximat

118 eprazole, VMAT2, histidine decarboxylase and chromogranin A mRNA abundance in gastric corpus, and pla

119 Chromogranin A mRNA responded to MAPK pathway manipulati

120 Chromogranin A mRNA showed a time-dependent 3.87-fold re

121 n L-DsRed fusion protein with enkephalin and chromogranin A neuropeptides that are present in secreto

122 isense PC1 induction, an approximately 66-kD chromogranin A NH2-terminal fragment as well as the pare

123 otyping, including catecholamine production, chromogranin A precursor, and its catestatin product.

124 Chromogranin A immunoblots revealed chromogranin A processing, from both the NH2 and COOH te

125 A series of chromogranin A promoter 5' deletion mutant/luciferase re

126 markedly diminished trans-activation of the chromogranin A promoter by PACAP.

127 r was in linkage disequilibrium with 1 major Chromogranin A promoter haplotype, although promoter hap

128 cis, activation by the cascade maps onto the chromogranin A promoter proximal CRE, which is both nece

129 , and calcium-dependent signals map onto the chromogranin A promoter proximal CRE.

130 oximal CRE box is entirely necessary for the chromogranin A promoter response to PACAP.

131 kinase blocked the response of a transfected chromogranin A promoter to nicotine or protein kinase C

132 antagonist KCREB blocked the response of the chromogranin A promoter to nicotine, cAMP, or MAPK pathw

133 protein kinase C mapped principally onto the chromogranin A promoter's cAMP response element (TGACGTA

134 ltimately relays the secretory signal to the chromogranin A promoter's CRE box in cis.

135 tion in a fashion similar to the transfected chromogranin A promoter, in both direction and magnitude

136 n enhanced basal as well as IGF-I-stimulated chromogranin A promoter.

137 fection of pathway components stimulated the chromogranin A promoter.

138 we employed a novel mouse strain harboring a chromogranin A promoter/firefly luciferase reporter tran

139 e obtained with a transfected 1,200-bp mouse chromogranin A promoter/luciferase reporter construct.

140 Transfected chromogranin A promoter/luciferase reporter constructs w

141 Generation of NOD mice lacking the chromogranin A protein (NOD.ChgA(-/-)) completely nullif

142 edistribution of desmoplakin, keratin 5, and chromogranin A proteins.

143 his peptide blocked the inhibitory effect of chromogranin A proteolytic fragments on nicotinic-stimul

144 ay not be solely explained by the absence of chromogranin A reactivity.

145 atecholamine release, and was shared by this chromogranin A region from several species.

146 ced secretion, transcriptional activation of chromogranin A remained unaltered.

147 sphatase and the regulated secretory protein chromogranin A resulted in an increased chromogranin sto

148 Plasma cortisol and chromogranin A showed a significant association that did

149 ization domain did not affect the sorting of chromogranin A to the regulated secretory pathway.

150 Thus, PACAP-evoked chromogranin A transcription and catecholamine secretion

151 -binding protein CREB, blunted activation of chromogranin A transcription by nicotine, phorbol ester,

152 We conclude that activation of chromogranin A transcription by secretory stimulation in

153 receptor antagonist PACAP6-38 impaired both chromogranin A transcription or catecholamine secretion

154 Therefore, we propose that PACAP signals to chromogranin A transcription through the CRE in cis, and

155 bited both forskolin and PACAP activation of chromogranin A transcription, revealing that PACAP-induc

156 timuli influence exocytotic secretion versus chromogranin A transcription.

157 Chromogranin A was identified as a promising marker for

158 a new phosphorylation site (S191) in bovine chromogranin A was identified.

159 eporter and the neuroendocrine-specific gene chromogranin A was induced 2-3.3-fold by insulin-like gr

160 Synthetic longer (chromogranin A(332-364)) and shorter (chromogranin A(344

161 trometry, a major catestatin form was bovine chromogranin A(332-364); identity of the peptide was con

162 alysis revealed two additional forms: bovine chromogranin A(333-364) and A(343-362).

163 omaffin granules, with the major form, human chromogranin A(340-372), bounded by dibasic sites.

164 onger (chromogranin A(332-364)) and shorter (chromogranin A(344-364)) versions of catestatin each inh

165 ratin 20), acinar (chymotrypsin), and islet (chromogranin A) cell markers was performed to analyze th

166 as associated with an objective biochemical (chromogranin A) response rate of 40%, and a radiologic r

167 marker MTA1, the apoptotic marker NALP, and chromogranin A) that define gut neuroendocrine cell beha

168 Although various biomarkers including CHGA (Chromogranin A), INSM1 (Insulinoma-associated protein 1)

169 biosynthesis of the major secreted protein (chromogranin A), that the activation is transcriptional,

170 Among 37 patients with elevated chromogranin A, 26 (70%) achieved normalization or more

171 tes highly O-glycosylated proteins including Chromogranin A, a key player in dense core granulogenesi

172 Serum chromogranin A, a marker for neuroendocrine tumors, is e

173 nase) blocked nicotinic or PMA activation of chromogranin A, although a dominant negative Ras mutant

174 ch activation, and secretory markers Mucin2, Chromogranin A, and Growth factor-independent 1 (Gfi1) w

175 Different amidation events on chromogranin A, and on peptides processed from proopiome

176 rade [poorly differentiated], respectively), chromogranin A, and proliferation index (Ki-67).

177 found extensive processing of catestatin in chromogranin A, as judged by catestatin radioimmunoassay

178 in positively for alpha-tubulin, mucins, and chromogranin A, as well as for endoderm transcription fa

179 ntestinal enteroendocrine cells positive for chromogranin A, but they had normal numbers of Paneth's,

180 Chromogranin A, chromogranin B, and secretogranin II, me

181 ocortin (POMC), provasopressin, prooxytocin, chromogranin A, chromogranin B, and secretogranin II.

182 Chromogranin A, coreleased with catecholamines by exocyt

183 Tissue morphology, abundance of chromogranin A, gut hormones, alpha-defensin, mucin 2, N

184 imulation of secretion in catecholamines and chromogranin A, indicating that secretion of solAPPcyt w

185 cells did not express defensin-5, Muc-2, or chromogranin A, indicating that they were not lineage co

186 The baseline levels of chromogranin A, neuron-specific enolase, and multiple so

187 We also measured fasting serum chromogranin A, neuron-specific enolase, gastrin, glucag

188 Elevated baseline chromogranin A, neuron-specific enolase, placental growt

189 hetic peptides spanning approximately 80% of chromogranin A, one (bovine chromogranin A344-364 [RSMRL

190 gen receptor, prostate specific antigen, and chromogranin A, respectively.

191 secretion also activates the biosynthesis of chromogranin A, the major protein released with catechol

192 lls, we studied the biosynthetic response of chromogranin A, the major soluble protein co-stored and

193 Such coupling triggers the biosynthesis of chromogranin A, the precursor of catestatin.

194 ynthesis of just released catecholamines and chromogranin A, the precursor of the catecholamine relea

195 gene-3; stem (BMI1, nestin); and chromaffin (chromogranin A, tyrosine hydroxylase) markers similar to

196 Here, we probed the role of the chromogranin A-derived peptide pancreastatin (PST: CHGA(

197 Pancreastatin (PST), a chromogranin A-derived peptide, is a potent physiologica

198 orms of gastrin in each, and pyloric mucosal chromogranin A-derived peptides were investigated in the

199 nces in the concentration of pyloric mucosal chromogranin A-derived peptides were recorded between in

200 d secretion in both neuroendocrine cells and chromogranin A-expressing COS7 cells used as a simplifie

201 psies confirmed the presence of the virus in chromogranin A-expressing epithelial cells, as it does i

202 as predominantly localized to epithelial and chromogranin A-positive endocrine cells.

203 et cell function while negatively regulating chromogranin A-positive enteroendocrine cell number.

204 inantly in intestinal epithelial cells, with chromogranin A-positive enteroendocrine cells (EECs) ide

205 istochemistry for cytokeratins 7 and 20, and Chromogranin A-proteins which have a well described expr

206 differentiation of thymocytes expressing the chromogranin A-reactive BDC-2.5 and BDC-10.1 TCRs or the

207 The frequencies of islet Ag-reactive chromogranin A-specific CD4(+) T cells and islet specifi

208 ed 2 neuroendocrine tumor markers, ASCL1 and chromogranin A.

209 of cells expressing the pan-endocrine marker chromogranin A.

210 and neuroendocrine markers synaptophysin and chromogranin A.

211 al neuroendocrine distribution of endogenous chromogranin A.

212 onserved N- and C-terminal regions of bovine chromogranin A.

213 gation properties as compared with wild-type chromogranin A.

214 0% of cells, and absence of chymotrypsin and chromogranin A.

215 related peptide, neurotensin, serotonin, and chromogranin A.

216 f chymotrypsin, and rare immunoreactivity to chromogranin A.

217 immunostaining for tau-2, synaptophysin, and chromogranin A.

218 n fragments, and was liberated from purified chromogranin A.

219 o label with antibodies specific for APP and chromogranin A.

220 euroendocrine cell markers Synaptophysin and Chromogranin A.

221 EVSSKDAAE, which is a degradation product of chromogranin A.

222 g, urinary catecholamines/metanephrines, and chromogranin A.

223 Chromogranins A and B (CGA and CGB) are high capacity, l

224 Chromogranins A and B (CGA and CGB), the major proteins

225 Chromogranins A and B and secretogranin II are a family

226 Chromogranins A and B are high capacity, low affinity ca

227 t express typical LDCV proteins, transfected chromogranins A, B, and brain-derived neurotrophic facto

228 and chemotherapy, presence of diabetes, and chromogranin-A (CgA) levels higher than 336 mug/L.

229 Fluorescent chromogranin-A positive EECs were purified and analysed

230 Plasma levels of cortisol and chromogranin-A were determined.

231 easing peptide, neuron-specific enolase, and chromogranin-A) were analyzed in 50 patients commencing

232 and-Factor[rs12829220] in the control group; Chromogranin-A[rs9658644], Cystatin-C[rs2424577] and Vit

233 oximately 80% of chromogranin A, one (bovine chromogranin A344-364 [RSMRLSFRARGYGFRGPGLQL], or catest

234 ine release-inhibitory fragment, catestatin (chromogranin A344-364), on agonist-induced desensitizati

235 elated best with synaptophysin compared with chromogranin and CD56/NCAM.

236 of interaction between the heterotetrameric chromogranin and heterotetrameric IP3 receptor but also

237 Size-fractionated chromogranins antagonized nicotinic cholinergic-stimulat

238 Chromogranins are a family of regulated secretory protei

239 Chromogranins are pro-hormone secretory proteins release

240 2+)-dependent aggregation and interaction of chromogranins, as well as several other matrix proteins,

241 olytic fragments of chromogranin A (CgA) and chromogranin B (CgB) represent the major proteins of the

242 at neonatal and adult cardiomyocytes express chromogranin B (CGB), a Ca(2+) binding protein that modu

243 For example, chromogranin B (CGB), a calcium binding protein found in

244 uroendocrine cells, chromogranin A (CGA) and chromogranin B (CGB), have been shown to undergo pH- and

245 tidylinositol-4-phosphate kinase (PIPKI) and chromogranin B (CGB), proteins acting synergistically to

246 the granin proteins chromogranin A (CgA) and chromogranin B (CgB); CgA- and CgB-derived peptides regu

247 Because the isoprostane and Chromogranin B (CHGB) traits shared rho(G), we examined

248 curring genetic variation in the promoter of chromogranin B (CHGB), a major constituent of catecholam

249 om chromogranin A (CHGA), and other CHGA- or chromogranin B (CHGB)-related peptides, in 545 US and 12

250 tory pathway; furthermore, lack of change in chromogranin B and secretogranin II cleavage after dimin

251 Chromogranin B and secretogranin II immunoblots showed n

252 pituitary cell line GH4C1 secretes granins (chromogranin B and secretogranin II) and prolactin by th

253 ce, which enhances accumulation of CD40L and chromogranin B granules at the human TFH cell synapse an

254 phenylethanolamine N-methyl transferase and chromogranin B mRNA was similar in TH-null and wild-type

255 y was confined to heavy fractions containing chromogranin B, a marker of large dense core vesicles.

256 otropin-releasing hormone, secretogranin II, chromogranin B, and pro-SAAS.

257 Chromogranin A, chromogranin B, and secretogranin II, members of the chr

258 provasopressin, prooxytocin, chromogranin A, chromogranin B, and secretogranin II.

259 ptides identified decreased transcription of chromogranin B, PCSK6, NPR1, and NFAT genes in cPC2-KOs.

260 cells contain dense-core granules marked by chromogranin B, which are normally found in neuronal pre

261 i significantly predicted vascular response: chromogranin B, which encodes a protein that catalyzes c

262 For example, 12 of the 13 chromogranin B-derived peptides found in the present stu

263 Two distinct chromogranin B-derived peptides result from cleavage at

264 Of these 13 chromogranin B-derived peptides, only five contain conse

265 yntaxin, SNAP-25, and N-cadherin, as well as chromogranin B.

266 Golgi network, contained carboxypeptidase E, chromogranin C, and IL-2, and had an electron-dense core

267 HSP70), vesicle- and synapse-related genes (chromogranin C, synaptotagmin IV), neurotransmitter/horm

268 [MiTF], HMB-45, MART-1, CK20, synaptophysin, chromogranin, CD1a, Ki-67) were then employed and the fi

269 Here, we show that chromogranin (CG) proteins undergo liquid-liquid phase s

270 boxyl-terminal amidated peptide derived from chromogranin (Cg)A, inhibits secretion of insulin and pa

271 n PC12 cells, these results demonstrate that chromogranins contain independent N- and C-terminal sort

272 techolamine secretory vesicle core proteins (chromogranins) contain an activity that inhibits catecho

273 a chromogranin fragment, which competed with chromogranin for its binding site on the InsP(3)R.

274 ET-1 was both correlated and associated with chromogranin fragment levels, and the 2 were influenced

275 raction between the two proteins by adding a chromogranin fragment, which competed with chromogranin

276 ion; the inhibitor was enriched in processed chromogranin fragments, and was liberated from purified

277 secretory granules of neuroendocrine cells, chromogranins have also been found in the lumen of the e

278 strin levels, mucosal histamine content, and chromogranin immunoreactivity.

279 tures of NE differentiation, as confirmed by chromogranin immunostaining and electron microscopy.

280 elial neoplasia showed NE differentiation by chromogranin immunostaining.

281 sulfide bond is not necessary for sorting of chromogranins in endocrine GH4C1 cells.

282 l disulfide bond is necessary for sorting of chromogranins in neuroendocrine PC12 cells.

283 Hence, in view of the abundance of chromogranins in secretory vesicles and their low pH- an

284 These results show that the InsP(3)R/chromogranin interaction amplifies Ca(2+) release from t

285 mplifies Ca(2+) release from the ER and that chromogranin is an essential component of this intracell

286 the upper limit of normal at baseline) serum chromogranin levels were observed, with confirmed comple

287 fic protein (NESP55), a maternally expressed chromogranin-like protein.

288 markers (MUC1, MUC2, MUC5AC, synaptophysin, chromogranin, neuron specific enolase, epidermal growth

289 f 58, 2%), myogenin (zero of eight, 0%), and chromogranin (one of 46, 2%); and variably reactive for

290 explored the role of these endoproteases in chromogranin processing in AtT-20 mouse pituitary cortic

291 on chromogranin A may be specific within the chromogranin/secretogranin protein family.

292 The chromogranin/secretogranin proteins are costored and cor

293 anin B, and secretogranin II, members of the chromogranin/secretogranin secretory protein family, are

294 In both IBS patients and HC, chromogranins, secretogranins and TLRs clustered togethe

295 tein chromogranin A resulted in an increased chromogranin storage in secretory granules, and stimulat

296 rostate-specific antigen, androgen receptor, chromogranin, synaptophysin, MIB-1, and alpha-methylacyl

297 activated by cytoplasmic InsP(3) and luminal chromogranin, the addition of the fragment reversed the

298 ed aggregation is necessary for sorting of a chromogranin to the regulated secretory pathway of endoc

299 involving kallikrein and Factor XII cleaves chromogranins to active compounds both in vivo and in vi

300 he interaction between the InsP(3) R and the chromogranins, we disrupted the interaction between the